Abstract YO36
Case summary
The frequency of BRAF mutation in non-small-cell lung cancer (NSCLC) is 1–2%. Some studies showed the patients with the mutation have poor outcomes to chemotherapy. Use of dabrafenib plus trametinib in BRAF V600E mutated NSCLC showed improvement in clinical outcomes of treatment-naïve and previously treated patients in phase II trials.
Pulmonary pleomorphic carcinoma (PPC) is a rare histologic subtype of NSCLC characterized by aggressive features with poor prognosis. Many of PPCs are reported to be resistant to chemotherapy and radiotherapy. Some types of targetable oncogenes have been detected in PPCs. However, the significance of BRAF mutation in PPC remains unclear.
Here we describe a patient with BRAF V600E mutated NSCLC with pleomorphic feature treated with BRAF and MEK inhibitor.
The patient is a 53-year-old woman. Chest CT scan revealed the mass invading the chest wall in the right middle lobe, hilar and mediastinal lymph node metastasis, and pleural dissemination. Biopsy from the primary tumor showed NSCLC-NOS. Gene analysis revealed the tumor was EGFR wild type, ALK/ROS-1 fusion negative, and PD-L1 TPS was 0%. Clinical stage was T4 N2 M1a, Stage IVA.
She received CDDP+GEM, Pemetrexed, and TS-1 sequentially, however, no response was obtained by these therapies. At the time of disease progression, right middle and lower lobe atelectasis was caused by the primary tumor and lymph nodes enlargement, and multiple bone metastasis emerged.
Re-biopsy was performed from the chest wall invasion site. The sample showed poor differentiated epithelial tumor cells and spindle cells suggesting pleomorphic feature and BRAF V600E was detected by next generation sequencing test.
Based on the result, we started dabrafenib plus trametinib therapy. The primary lesion and hilar lymph nodes rapidly shrunk resulting in atelectasis resolving on the chest X-ray in two weeks. The CT scan revealed dramatic tumor response in all metastatic legions. The response continued for about 10 months.
To best of our knowledge, few BRAF mutation positive NSCLC with pleomorphic feature cases have been reported. This case suggests that BRAF V600E mutation is also an important therapeutic target in PPC as much as in other histology.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
284P - Differences in disease characteristics and survival outcomes of follicular lymphoma in young adults and older population: An institutional analysis
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract
285TiP - Phase II, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667
Presenter: Christine Mauz-koerholz
Session: Poster display session
Resources:
Abstract
294P - Validation of the 8th edition of AJCC/UICC staging system for nasopharyngeal carcinoma: Results from a non-endemic cohort with long-term follow-up
Presenter: Li-rong Wu
Session: Poster display session
Resources:
Abstract
295P - Development and validation of M1 substages for previously untreated metastatic nasopharyngeal carcinoma
Presenter: Sik Kwan Chan
Session: Poster display session
Resources:
Abstract
296P - Nasopharyngeal carcinoma: A retrospective review of outcome in a single institution
Presenter: Wan Ping Ch' ng
Session: Poster display session
Resources:
Abstract
297P - Global longitudinal assessment of treatment outcomes in nasopharyngeal carcinoma (GLANCE-NPC) study
Presenter: Myung-Ju Ahn
Session: Poster display session
Resources:
Abstract
298P - Long-term complication and outcomes after induction chemotherapy with TPF followed by chemoradiotherapy for nasopharyngeal cancer
Presenter: Sang-Hee Cho
Session: Poster display session
Resources:
Abstract
299P - Weekly versus triweekly concurrent chemoradiation for nasopharyngeal cancer
Presenter: Sudibio Sudibio
Session: Poster display session
Resources:
Abstract
300P - Endoscopic nasopharyngectomy for localized stage I nasopharyngeal carcinoma
Presenter: Ming-Yuan Chen
Session: Poster display session
Resources:
Abstract
301P - Oncological outcome following 3 Drug NACT for Bucco-Alveolar carcinoma with Supra-notch ITF extension
Presenter: Karan Gupta
Session: Poster display session
Resources:
Abstract